Webinar on Addressing MARSI in Vascular Access: The Role of Skin Integrity in Infection Prevention, Presented by Covalon
21 Juin 2023 - 1:30PM
Business Wire
Registration now open: Save patient skin and
stop cringeworthy dressing trauma
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV; OTCQX: CVALF), an advanced medical technologies company, today
announced an expert-led webinar titled “Addressing MARSI in
Vascular Access: The Role of Skin Integrity in Infection
Prevention” will be held on Thursday, June 22, 2023 at 1pm ET.
Whether it’s placing an IV-line, checking vitals, or
administering life-saving treatment, patient care begins with the
skin. Yet, medical adhesive related skin injury (MARSI) affects 1
in 5 vascular access patients, with rates of up to 55% in pediatric
populations. MARSI occurs when medical adhesives – peeled away from
raw, vulnerable skin – cause the surface layers of the skin to be
torn. Damage to the skin doesn’t just cause pain, trauma, and
ongoing discomfort; it can result in harmful bacteria finding their
way into the skin tissues of surgical incisions, IV sites, or the
patient’s bloodstream.
Healing shouldn’t hurt – and Covalon is able to provide
compassionate care technology that can help hospitals move beyond
traditional acrylic-based dressings that can create wounds, cause
scarring and delay healing. Preventing and saving skin from
reactions, tears, and burns is much easier than treating them.
Healthcare practitioners are invited to join this webinar designed
to highlight the challenges of medical adhesive-related skin
injuries and best practices to protect patient skin and prevent
infection.
Takeaways from the webinar include:
- Insights into the challenges associated with MARSI
- Best practices for maintaining skin integrity
- New strategies and innovative technology to prevent MARSI
Webinar Details:
Title: Addressing MARSI in Vascular Access: The Role of
Skin Integrity in Infection Prevention
Presentation by: Sandy M. Conn, BSN, RN, CPN, WCC, Wound
and Skin Care Expert with over 30 years of experience in Pediatric
Critical Care
Date: Thursday, June 22, 2023, 1pm ET Registration
Link: Addressing MARSI in Vascular Access Hashtags:
#MARSI, #infectionprevention, #compassionatecare
Choosing the right medical dressing for a patient can make the
difference between pain vs comfort, infection vs healing, skin
injury vs skin integrity. Covalon’s soft silicone dressings provide
gentle, non-compromisingly effective care:
- CovaClear® IV – utilizes soft silicone adhesive technology to
help protect patients from skin injuries, but does not incorporate
antimicrobials, for use with patients who either do not require or
cannot tolerate antimicrobials.
- IV Clear® - the world’s only dual-antimicrobial vascular access
dressing that offers complete transparency at and around the
insertion site for easy daily assessment. It also utilizes soft
silicone adhesive technology to minimize skin injuries and preserve
skin barrier functions, and incorporates safe amounts of
antimicrobials, without sacrificing efficacy, to protect against
chemical irritation.
- SurgiClear® - the world's only dual-antimicrobial clear
postoperative dressing that provides full surgical site visibility,
allowing for visual site inspection and thus eliminating the need
for early and multiple dressing removals.
For healthcare providers who are not able to attend the webinar
but are interested in learning more about Covalon’s solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
About Covalon Covalon Technologies Ltd. is a
patient-driven medical device company, built on the relentless
pursuit to help the most vulnerable patients have a better chance
at healing. Through a strong portfolio of patented technologies and
solutions for advanced wound care, infection prevention, and
medical device coatings, we offer innovative, gentler, and more
compassionate options for patients to heal with less infections,
less pain, and better outcomes. Our solutions are designed for
patients and made for care providers. Covalon leverages its
patented medical technology platforms and expertise in two ways:
(i) by developing products that are sold under Covalon’s name; and
(ii) by developing and commercializing medical products for other
medical companies under development and license contracts. The
Company is listed on the TSX Venture Exchange, having the symbol
COV and trades on the OTCQX Market under the symbol CVALF. To learn
more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results “may”,
“could”, “would”, “might”, “will” or “will be taken”, “occur”, or
“be achieved”. In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management’s expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the “Risks
and Uncertainties” section of our management’s discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which is available on the Company’s
profile at www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621016102/en/
To learn more about Covalon, please contact: Brian Pedlar, CEO,
Covalon Technologies Ltd. Email: bpedlar@covalon.com Phone:
905.568.8400 x 233 Toll-Free: 1.877.711.6055 Website:
https://covalon.com/ Twitter: @covalon
Covalon Technologies (TSXV:COV)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Covalon Technologies (TSXV:COV)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024